Polymerase chain reaction (PCR) ready mix or master mix
The novel PCR-ready mix addresses suboptimal issues in existing PCR mixes by optimizing components like Tris buffer, TMAC, TMAO, and L-Carnitine for enhanced fidelity and uniformity in PCR reactions, especially in AT- and GC-rich regions.
Patent Information
- Application Number
- PCT/EP2026/062805
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
Existing PCR master mixes and ready mixes are often suboptimal for certain polymerases, leading to inefficiencies such as low enzyme activity, inhibitory contaminants, improper buffer composition, imbalanced dNTP concentrations, and heat instability, which can affect yield, sensitivity, and fidelity in PCR reactions, especially for AT- and GC-rich regions.
A novel PCR-ready master mix composition optimized for a modified DNA polymerase with high affinity and intrinsic processivity, incorporating specific concentrations of Tris buffer, tetramethylammonium chloride (TMAC) and tetramethylammonium oxalate (TMAO) for improved nucleic acid hybridization, along with magnesium chloride, gelatin, glycerol, and L-Carnitine, to enhance PCR performance.
The optimized master mix composition achieves superior PCR performance with improved fidelity, yield, and uniform coverage, particularly in challenging templates, by ensuring optimal enzyme activity and stability across varying GC content.
Smart Images

Figure 00000037_0000 
Figure 00000038_0000 
Figure 00000039_0000
Abstract
Description
P40072-WQ-1POLYMERASE CHAIN REACTION (PCR) READY MIX OR MASTER MIXCROSS REFERENCE TO RELATED PATENT APPLICATION
[0001] This patent application claims priority from U.S. Provisional Patent Application No. 63 / 800,092, filed May 5, 2025, which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION
[0002] The present disclosure relates to the field of molecular analysis of nucleic acids. In particular, the present disclosure relates to the field of amplification of particular target nucleic acids sequences by polymerase chain reaction (PCR). In even more particularity, the present disclosure is related to the field of reagents (e.g, ready mixes or master mixes) for use in PCR reactions.BACKGROUND OF THE INVENTION
[0003] Polymerase chain reaction (PCR) is a widely used molecular biology technique for amplification of specific sequences (such as nucleic acid sequences, such as deoxyribonucleic acid (DNA)). PCR allows researchers to generate millions of copies of a particular sequence (e.g., DNA segment), starting from a very small amount of starting material (e.g., DNA).
[0004] The basic steps of PCR involve the steps of: (1) denaturation, (2) annealing, and (3) extension. In the denaturation step, the double-stranded DNA template, which is the DNA sample containing the region of interest to be amplified, is heated (e.g., to around 94-98°C), to break down the hydrogen bonds between the two strands, which results in singlestranded DNA. During the annealing step, the reaction temperature is lowered (e.g., to around 50-65°C), to allow short primers (e.g., DNA primers) to attach, or anneal, to the complementary sequences on the single-stranded DNA template. Primers are short singlestranded sequences of nucleic acids (e.g, DNA primers) that are complementary to the sequences that flank the target region. During the extension step, the temperature is raised to the optimal working temperature of a polymerase enzyme (e.g, DNA polymerase), which is usually around 72°C. The polymerase enzyme extends the annealed primers by adding deoxynucleotide triphosphates (dNTPs) to the 3’ ends of the annealed primers, synthesizingnew DNA strands, which are complementary to the template. DNA polymerases are enzymes that synthesize new DNA strands (e.g., Taq polymerase), and dNTPs are the building blocks for new DNA strand synthesis, and include dATP, dCTP, dGTP, and dTTP).
[0005] The basic steps of PCR, described previously, are considered to make up one single cycle of PCR. Many PCR runs comprise a number of cycles, for example 20-40 cycles. The whole PCR process can be completed in just a few hours, and can amplify DNA from even a single copy of the starting template, thereby making PCR an extremely powerful and sensitive technique for genetic analysis.
[0006] PCR is often conducted in a solution, which provides optimal conditions for DNA polymerase activity, and multiple cycles of PCR reactions. This buffer is often referred to as a master mix (or mastermix) or a ready mix (or readymix). A PCR master mix or ready mix is a pre-mixed solution that contains most, if not all, of the components necessary for performing PCR reactions. Master mixes and ready mixes greatly simplify the preparation process, and reduces the chances of contamination and pipetting errors. A typical PCR master mix or ready mix will include a DNA polymerase, dNTPs, a buffer, and stabilizers and enhancers. The DNA polymerase can be any enzyme that synthesizes new strands (e.g., new DNA strands), with some examples including Taq polymerase, as well as other thermostable DNA polymerases. The dNTPs comprise a mixture of deoxyribonucleotide triphosphates (e.g, dATP, dCTP, dGTP, and dTTP), which are the building blocks for new nucleic acid (e.g, DNA) synthesis. The buffer component of a master mix or ready mix typically comprises a solution that maintains the optimal pH and ionic conditions for the enzyme (e.g, polymerase) activity, and will often include MgCh, which is essential for DNA polymerase function. Stabilizers and enhancers might also be included in a master mix or ready mix, which could include substances that improve the robustness and / or efficiency of the PCR reaction, and can include components, such as bovine serum albumin (BSA), dimethyl sulfoxide (DMSO), or glycerol.
[0007] Although some PCR master mixes and ready mixes are suitable for many PCR reactions, there are some PCR master mixes and ready mixes that are specifically formulated for use with certain polymerases, and might not be suitable for other polymerases. The composition of a PCR master mix or ready mix, including buffering agents, salts, magnesium concentration, stabilizers, and enhancers, can vary significantly based on the requirements of different polymerases. Some factors to consider when choosing a PCR master mix or ready mix that is compatible with a specific polymerase include enzyme activity, fidelity, processivity, supplementary components, and temperature stability. Different enzymes, suchas polymerases, can operate optimally at different pH levels and ionic strengths. Also, certain high-fidelity polymerases may require specific enhancers or stabilizers not found in standard master mixes or ready mixes. Regarding processivity, some polymerases, especially those used in long-range PCR, need specific formulations to maintain activity over long templates. Other additives, like DMSO, betaine, or proprietary stabilizers, may improve the performance of specific polymerases, while inhibiting the performance of other polymerases. Regarding temperature stability, master mixes or ready mixes designed for hot-start polymerases contain certain inhibitors that need to be inactivated by heat, while others are not compatible with such inhibitors. Thus, certain polymerases might work optimally or work better, in certain master mix or ready mix compositions or conditions, as compared to other polymerases. Indeed, in order to optimize an enzyme’s performance, such as a polymerase’s performance, a uniquely tailored master mix or ready mix can be invented and employed.
[0008] Some PCR master mixes or ready mixes might be suboptimal. Such master mixes or ready mixes might include mixtures that do not produce the desired results, due to various inefficiencies or imbalances in their components. Certain PCR master mixes and ready mixes might be suboptimal because it might result in low enzyme activity / efficiency, may contain inhibitory contaminants, might have an improper buffer composition (e.g., pH or ionic strength), imbalanced dNTP concentrations, incorrect MgCU concentration, or heat instability of components. Thus, not every PCR master mix or ready mix is ideal for every polymerase, and certain polymerases might benefit by inclusion of a specific or unique master mix or ready mix.
[0009] Described herein, is a novel PCR-ready master mix or ready mix composition. This master mix or ready mix composition is ideally suited for activity of a particular polymerase that has been engineered to have an increased affinity for DNA, without the need for accessory protein domains, and which has intrinsic high processivity properties, resulting in significant improvements to yield, sensitivity, speed, target length, low error rates, and the ability to amplify difficult templates (e.g., AT- and GC-rich regions). In particular, the master mix and ready mix described herein, is optimal for the modified DNA polymerase as described in the following U.S. patents: U.S. Patent Nos. 9,023,633; 9,388,396; and 8,481,685, all of which are incorporated herein by reference, in their entireties. In particular, the disclosed master mixes or ready mixes are engineered to exhibit superior performance in PCR, resulting in improved fidelity i.e., lower error rates), and improved / superior coverage uniformity.SUMMARY OF THE INVENTION
[0010] Certain embodiments of the present disclosure relate to master mix and / or ready mix solution compositions, for use in nucleic acid amplification reactions, such as PCR. In some embodiments, the master mix or ready mix compositions comprise certain components, such as buffers, salts, chemical compounds that improve nucleic acid hybridization (such as quaternary ammonium salts (e.g, tetramethylammonium chloride (TMAC) and tetramethylammonium oxalate (TMAO)), quaternary ammonium compounds, alcohols, polymerase co-factors, dNTPs, and polymerases. Certain embodiments also include methods of using the master mixes and / or ready mixes in nucleic acid amplification reactions, such as PCR amplifications.
[0011] One embodiment of the disclosure is directed to a PCR master mix composition, wherein PCR the master mix composition comprises the following: (a) between about 80-120 mM of a buffer; (b) between about 4-100 mM of at least one chemical compound that improves nucleic acid hybridization; (c) between about 2-4 mM of a polymerase co-factors; (d) between about 0.01-0.10% (w / v) of a hydrogel; (e) between about 1-10% (v / v) of a polyol; and (f) between about 100-500 mM of a quaternary ammonium compound. In one embodiment, the buffer is a Tris buffer. In one embodiment, the Tris buffer is at a concentration of about 100 mM. In one embodiment, the Tris buffer is at a concentration of 100 mM. In one embodiment, the pH of the Tris Buffer is set to a specific value by sulphuric acid (H2SO4) addition. In one embodiment, the at least one chemical compound that improves nucleic acid hybridization is tetramethylammonium chloride (TMAC). In one embodiment, the TMAC is at a concentration of between about 60-100 mM. In one embodiment, the TMAC is at a concentration of about 80 mM. In one embodiment, the TMAC is at a concentration of 80 mM. In one embodiment, the at least one chemical compound that improves nucleic acid hybridization is tetramethylammonium oxalate (TMAO). In one embodiment, the TMAO is at a concentration of between about 4-8 mM. In one embodiment, the TMAO is at a concentration of about 6 mM. In one embodiment, the TMAO is at a concentration of 6 mM. In one embodiment, the at least one chemical compound that improves nucleic acid hybridization consists of two chemical compounds that improve nucleic acid hybridization. In one embodiment, the two chemical compounds that improve nucleic acid hybridization are TMAC and TMAO. In one embodiment, the TMAC is at a concentration of between about 60-100 mM. In one embodiment, the TMAC is at a concentration of about 80 mM. In one embodiment, the TMAC is at a concentration of 80 mM. In one embodiment, the TMAO is at a concentration of between about 4-8 mM. In oneembodiment, the TMAO is at a concentration of about 6 mM. In one embodiment, the TMAO is at a concentration of 6 mM. In one embodiment, the polymerase co-factor is selected from the following group of polymerase co-factors: magnesium chloride (MgCh), Manganese Chloride (MnCh), Cobalt Chloride (C0CI2), Zinc Chloride (ZnCh), and Calcium Chloride (CaCh). In one embodiment, the polymerase co-factor is MgCh. In one embodiment, the MgChis at a concentration of about 2.75 mM. In one embodiment, the MgCh is at a concentration of 2.75 mM. In one embodiment, the hydrogel is selected from the following group of hydrogels: gelatin, agarose, alginate, hyaluronic acid, and chitosan. In one embodiment, the hydrogel is gelatin. In one embodiment, the gelatin is at a concentration of about 0.04% (w / v). In one embodiment, the gelatin is at a concentration of 0.04% (w / v). In one embodiment, the polyol is selected from the following group of polyols: glycerol, glycerin, sorbitol, mannitol, xylitol, erythritol, maltitol, and isomalt. In one embodiment, the polyol is glycerol. In one embodiment, the glycerol is at a concentration of about 5% (v / v). In one embodiment, the glycerol is at a concentration of 5% (v / v). In one embodiment, the quaternary ammonium compound is L-Camitine. In one embodiment, the L-Carnitine is at a concentration of about 300 mM. In one embodiment, the L-Camitine is at a concentration of 300 mM. In one embodiment, the PCR master mix further comprises dNTPs. In one embodiment, the dNTPs are at a concentration between about 0.1-0.5 mM. In one embodiment, the dNTPs are at a concentration of about 0.2 mM. In one embodiment, the dNTPs are at a concentration of 0.2 mM. In one embodiment, the PCR master mix further comprises a DNA polymerase. In one embodiment, the DNA polymerase is a modified DNA polymerase. In one embodiment, the DNA polymerase is at a concentration between about 200-800 ng. In one embodiment, the DNA polymerase is at a concentration of about 600 ng. In one embodiment, the DNA polymerase is at a concentration of about 600 ng in 50 pl, which is 12 ng / pl. In one embodiment, the DNA polymerase is at a concentration of 600 ng. In one embodiment, the DNA polymerase is at a concentration of 600 ng in 50 pl, which is 12 ng / pl. One embodiment is directed to a reaction mixture comprising the PCR master mix composition, described herein. One embodiment is directed to a kit comprising the PCR master mix composition described herein.
[0012] Another embodiment is directed to a reaction mixture comprising a PCR master mix composition, wherein the PCR master mix composition comprises the following: (a) between about 8-120 mM of a buffer; (b) between about 4-100 mM of at least one chemical compound that improves nucleic acid hybridization; (c) between about 2-4 mM of a polymerase co-factor; (d) between about 0.01-0.10% (w / v) of a hydrogel; (e) between about1-10% (v / v) of a polyol; and (f) between about 100-500 mM of a carnitine. In one embodiment, the buffer is a Tris buffer. In one embodiment, the Tris buffer is at a concentration of about 100 mM. In one embodiment, the Tris buffer is at a concentration of 100 mM. In one embodiment, the pH of the Tris Buffer is set to a specific value by sulphuric acid (H2SO4) addition. In one embodiment, the at least one chemical compound that improves nucleic acid hybridization is tetramethylammonium chloride (TMAC). In one embodiment, the TMAC is at a concentration of between about 60-100 mM. In one embodiment, the TMAC is at a concentration of about 80 mM. In one embodiment, the TMAC is at a concentration of 80 mM. In one embodiment, the at least one chemical compound that improves nucleic acid hybridization is tetramethylammonium oxalate (TMAO). In one embodiment, the TMAO is at a concentration of between about 4-8 mM. In one embodiment, the TMAO is at a concentration of about 6 mM. In one embodiment, the TMAO is at a concentration of 6 mM. In one embodiment, the at least one chemical compound that improves nucleic acid hybridization consists of two chemical compounds that improve nucleic acid hybridization. In one embodiment, the two chemical compounds that improve nucleic acid hybridization are TMAC and TMAO. In one embodiment, the TMAC is at a concentration of between about 60-100 mM. In one embodiment, the TMAC is at a concentration of about 80 mM. In one embodiment, the TMAC is at a concentration of 80 mM. In one embodiment, the TMAO is at a concentration of between about 4-8 mM. In one embodiment, the TMAO is at a concentration of about 6 mM. In one embodiment, the TMAO is at a concentration of 6 mM. In one embodiment, the polymerase co-factor is selected from the following group of polymerase co-factors: magnesium chloride (MgCh), Manganese Chloride (MnCh), Cobalt Chloride (C0CI2), Zinc Chloride (ZnCh), and Calcium Chloride (CaCh). In one embodiment, the polymerase co-factor is MgCh. In one embodiment, the MgCh is at a concentration of about 2.75 mM. In one embodiment, the MgCh is at a concentration of 2.75 mM. In one embodiment, the hydrogel is selected from the following group of hydrogels: gelatin, agarose, alginate, hyaluronic acid, and chitosan. In one embodiment, the hydrogel is gelatin. In one embodiment, the gelatin is at a concentration of about 0.04% (w / v). In one embodiment, the gelatin is at a concentration of 0.04% (w / v). In one embodiment, the polyol is selected from the following group of polyols: glycerol, glycerin, sorbitol, mannitol, xylitol, erythritol, maltitol, and isomalt. In one embodiment, the polyol is glycerol. In one embodiment, the glycerol is at a concentration of about 5% (v / v). In one embodiment, the glycerol is at a concentration of 5% (v / v). In one embodiment, the quaternary ammonium compound is L-Camitine. In one embodiment, the L-Carnitine is at aconcentration of about 300 mM. In one embodiment, the L-Camitine is at a concentration of 300 mM. In another embodiment, the reaction mixture further comprises dNTPs. In one embodiment, the dNTPs are at a concentration between about 0.1 -0.5 mM. In one embodiment, the dNTPs are at a concentration of about 0.2 mM. In one embodiment, the dNTPs are at a concentration of 0.2 mM. In another embodiment, the reaction mixture further comprises a DNA polymerase. In one embodiment, the DNA polymerase is a modified DNA polymerase. In one embodiment, the DNA polymerase is at a concentration between about 200-800 ng. In one embodiment, the DNA polymerase is at a concentration of about 600 ng. In one embodiment, the DNA polymerase is at a concentration of about 600 ng in 50 pl, which is 12 ng / pl. In one embodiment, the DNA polymerase is at a concentration of 600 ng. In one embodiment, the DNA polymerase is at a concentration of 600 ng in 50 pl, which is 12 ng / pl.
[0013] One embodiment of the disclosure is directed to a kit comprising a PCR master mix composition, wherein the master mix composition comprises the following: (a) between about 80-120 mM of a buffer; (b) between about 4-100 mM of at least one chemical compound that improves nucleic acid hybridization; (c) between about 2-4 mM of a polymerase co-factor; (d) between about 0.01-0.10% (w / v) of a hydrogel; (e) between about 1-10% (v / v) of a polyol; and (f) between about 100-500 mM of a carnitine. In one embodiment, the buffer is a Tris buffer. In one embodiment, the Tris buffer is at a concentration of about 100 mM. In one embodiment, the Tris buffer is at a concentration of 100 mM. In one embodiment, the pH of the Tris Buffer is set to a specific value by sulphuric acid (H2SO4) addition. In one embodiment, the at least one chemical compound that improves nucleic acid hybridization is tetramethylammonium chloride (TMAC). In one embodiment, the TMAC is at a concentration of between about 60-100 mM. In one embodiment, the TMAC is at a concentration of about 80 mM. In one embodiment, the TMAC is at a concentration of 80 mM. In one embodiment, the at least one chemical compound that improves nucleic acid hybridization is tetramethylammonium oxalate (TMAO). In one embodiment, the TMAO is at a concentration of between about 4-8 mM. In one embodiment, the TMAO is at a concentration of about 6 mM. In one embodiment, the TMAO is at a concentration of 6 mM. In one embodiment, the at least one chemical compound that improves nucleic acid hybridization consists of two chemical compounds that improve nucleic acid hybridization. In one embodiment, the two chemical compounds that improve nucleic acid hybridization are TMAC and TMAO. In one embodiment, the TMAC is at a concentration of between about 60-100 mM. In one embodiment, the TMAC is at aconcentration of about 80 mM. In one embodiment, the TMAC is at a concentration of 80 mM. In one embodiment, the TMAO is at a concentration of between about 4-8 mM. In one embodiment, the TMAO is at a concentration of about 6 mM. In one embodiment, the TMAO is at a concentration of 6 mM. In one embodiment, the polymerase co-factor is selected from the following group of polymerase co-factors: magnesium chloride (MgCh), Manganese Chloride (MnCh), Cobalt Chloride (C0CI2), Zinc Chloride (ZnCh), and Calcium Chloride (CaCh). In one embodiment, the polymerase co-factor is MgCh. In one embodiment, the MgCh is at a concentration of about 2.75 mM. In one embodiment, the MgCh is at a concentration of 2.75 mM. In one embodiment, the hydrogel is selected from the following group of hydrogels: gelatin, agarose, alginate, hyaluronic acid, and chitosan. In one embodiment, the hydrogel is gelatin. In one embodiment, the gelatin is at a concentration of about 0.04% (w / v). In one embodiment, the gelatin is at a concentration of 0.04% (w / v). In one embodiment, the polyol is selected from the following group of polyols: glycerol, glycerin, sorbitol, mannitol, xylitol, erythritol, maltitol, and isomalt. In one embodiment, the polyol is glycerol. In one embodiment, the glycerol is at a concentration of about 5% (v / v). In one embodiment, the glycerol is at a concentration of 5% (v / v). In one embodiment, the quaternary ammonium compound is L-Camitine. In one embodiment, the L-Carnitine is at a concentration of about 300 mM. In one embodiment, the L-Camitine is at a concentration of 300 mM. In one embodiment, the kit further comprises dNTPs. In one embodiment, the dNTPs are at a concentration between about 0.1-0.5 mM. In one embodiment, the dNTPs are at a concentration of about 0.2 mM. In one embodiment, the dNTPs are at a concentration of 0.2 mM. In one embodiment, the kit further comprises a DNA polymerase. In one embodiment, the DNA polymerase is a modified DNA polymerase. In one embodiment, the DNA polymerase is at a concentration between about 200-800 ng. In one embodiment, the DNA polymerase is at a concentration of about 600 ng. In one embodiment, the DNA polymerase is at a concentration of about 600 ng in 50 pl, which is 12 ng / pl. In one embodiment, the DNA polymerase is at a concentration of 600 ng. In one embodiment, the DNA polymerase is at a concentration of 600 ng in 50 pl, which is 12 ng / pl.
[0014] One embodiment of the disclosure is directed to a master mix composition for amplification of nucleic acids, wherein the composition comprises the following: (a) between about 10-300 mM of a buffer; (b) between about 10-200 mM of a quaternary ammonium compound; (c) between about 2-20 mM of an oxalate salt; and (d) between about 1-5 mM of one or more polymerase co-factors. In another embodiment, the oxalate salt is tetramethylammonium oxalate (TMAO). In another embodiment, the TMAO is at aconcentration of between about 2-10 mM. In another embodiment, the composition further comprises the following: (e) between about 50-600 mM of a Carnitine. In another embodiment, the Carnitine may be either the D-Camitine or L-Camitine. In another embodiment, the Carnitine is D-Camitine. In another embodiment, the Carnitine is L-Camitine. In another embodiment, the L-Camitine is at a concentration of between about 50-400 mM. In another embodiment, the quaternary ammonium compound is tetramethylammonium chloride (TMAC). In another embodiment, the composition further comprises the following: (e) one or more DNA polymerases. In another embodiment, the composition further comprises the following: (e) deoxynucleoside triphosphates (dNTPs). In another embodiment, the one or more polymerase co-factors is magnesium ions (Mg2+). In another embodiment, the buffer is a Tris buffer. In another embodiment, the oxalate salt is TMAO, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine. In another embodiment, the quaternary ammonium compound is TMAC. In another embodiment, the oxalate salt is TMAO, the quaternary ammonium compound is TMAC, and the composition further comprises between about 50-600 mM of L-Camitine. In another embodiment, the composition is a polymerase chain reaction (PCR) master mix composition, and the amplification is by polymerase chain reaction (PCR). In another embodiment, the disclosure is directed to a method of conducting polymerase chain reaction (PCR), wherein the PCR reaction is conducted in the master mix composition of claim.
[0015] One embodiment of the disclosure is directed a polymerase chain reaction (PCR) master mix composition, wherein the PCR master mix composition comprises the following: (a) between about 10-300 mM of a buffer; (b) between about 10-200 mM of a quaternary ammonium compound; (c) between about 2-20 mM of an oxalate salt; and (d) between about 1-5 mM of one or more polymerase co-factors. In one embodiment, the oxalate salt is tetramethylammonium oxalate (TMAO). In one embodiment, the TMAO is at a concentration of between about 2-10 mM. In one embodiment, the PCR master mix composition further comprises the following: (e) between about 50-600 mM of a Carnitine. In one embodiment, the Carnitine may be either the D-Camitine or L-Camitine. In one embodiment, the Carnitine is D-Camitine. In one embodiment, the Carnitine is L-Camitine. In one embodiment, the L-Camitine is at a concentration of between about 50-400 mM. In one embodiment, the quaternary ammonium compound is tetramethylammonium chloride (TMAC). In one embodiment, the PCR master mix composition further comprises the following: (e) one or more DNA polymerases. In one embodiment, the PCR master mix composition further comprises the following: (e) deoxynucleoside triphosphates (dNTPs). Inone embodiment, the one or more polymerase co-factors is magnesium ions (Mg2+). In one embodiment, the buffer is a Tris buffer. In one embodiment, the oxalate salt is TMAO, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine. In one embodiment, the quaternary ammonium compound is TMAC. In one embodiment, the oxalate salt is TMAO, the quaternary ammonium compound is TMAC, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine. In one embodiment, the disclosure is directed to a method of conducting PCR, wherein the PCR reaction is conducted in the PCR master mix composition.
[0016] One embodiment of the disclosure is directed to a PCR master mix composition, wherein the PCR master mix composition comprises the following: (a) between about 10-300 mM of a buffer; (b) between about 10-200 mM of a quaternary ammonium compound; (c) between about 2-20 mM of an oxalate salt; (d) between about 1-5 mM of one or more polymerase co-factors; and (e) between about 50-600 mM of a Carnitine. In one embodiment, the oxalate salt is tetramethyl ammonium oxalate (TMAO). In one embodiment, the TMAO is at a concentration of between about 2-10 mM. In one embodiment, the Carnitine may be either the D-Camitine or L-Carnitine. In one embodiment, the Carnitine is D-Camitine. In one embodiment, the Carnitine is L-Camitine. In one embodiment, the L-Camitine is at a concentration of between about 50-400 mM. In one embodiment, the quaternary ammonium compound is tetramethylammonium chloride (TMAC). In one embodiment, the PCR master mix composition further comprises the following: (f) one or more DNA polymerases. In one embodiment, the PCR master mix composition further comprises the following: (f) deoxynucleoside triphosphates (dNTPs). In one embodiment, the buffer is a Tris buffer. In one embodiment, the one or more polymerase co-factors is magnesium ions (Mg2+). In one embodiment, the oxalate salt is TMAO, and the Carnitine is L-Camitine. In one embodiment, the quaternary ammonium compound is TMAC. In one embodiment, the oxalate salt is TMAO, the quaternary ammonium compound is TMAC, and Carnitine is L-Camitine. In one embodiment, the disclosure is directed to a method of conducting PCR, wherein the PCR reaction is conducted in the PCR master mix composition.
[0017] In another embodiment, the disclosure is directed to a method of amplifying one or more target nucleic acids by PCR, wherein the amplification is conducted in a PCR master mix composition, wherein the PCR master mix composition comprises the following: (a) between about 10-300 mM of a buffer; (b) between about 10-200 mM of a quaternary ammonium compound; (c) between about 2-20 mM of an oxalate salt; and (d) between about 1-5 mM of one or more polymerase co-factors. In one embodiment, the oxalate salt istetramethylammonium oxalate (TMAO). In one embodiment, the TMAO is at a concentration of between about 2-10 mM. In one embodiment, the PCR master mix composition further comprises the following: (e) between about 50-600 mM of a Carnitine. In one embodiment, the Carnitine may be either the D-Camitine or L-Camitine. In one embodiment, the Carnitine is D-Camitine. In one embodiment, the Carnitine is L-Camitine. In one embodiment, the L-Camitine is at a concentration of between about 50-400 mM. In one embodiment, the quaternary ammonium compound is tetramethylammonium chloride (TMAC). In one embodiment, the method further comprises the following: (e) one or more DNA polymerases. In one embodiment, the method of claim further comprises the following: (e) deoxynucleoside triphosphates (dNTPs). In one embodiment, the one or more polymerase co-factors is magnesium ions (Mg2+). In one embodiment, the buffer is a Tris buffer. In one embodiment, the oxalate salt is TMAO, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine. In one embodiment, the quaternary ammonium compound is TMAC. In one embodiment, the oxalate salt is TMAO, the quaternary ammonium compound is TMAC, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine. In one embodiment, the PCR exhibits improved fidelity and / or improved uniformity across content of variable GC content, as compared to PCR conducted without the master mix composition. In one embodiment, primer extension during the PCR is performed at 68°C.BRIEF DESCRIPTION OF DRAWINGS
[0018] The following includes a brief description of the drawings.
[0019] FIG. 1 depicts Table 1, which shows a composition of the PCR master mix or ready mix, described herein, including the various components that make up the PCR master mix or ready mix, and its concentrations (in the master mix and ready mix and in the PCR reaction).
[0020] FIG. 2 depicts Table 2, which shows the PCR thermal cycling conditions using the compositions of the PCR master mix and ready mix, as described herein.
[0021] FIG. 3A and FIG. 3B show the results from the experiments described in Example 2. In particular, FIG. 3A shows the total PCR error percentage as determined by whole genome sequencing (WGS) analysis of amplified sequencing libraries, where TMAO was added at 0 mM, 2 mM, 6 mM, and 8 mM end concentrations to the KAPA2G Robust HotStart ReadyMix. FIG. 3B shows the coverage uniformity as determined by WGS analysisof amplified sequencing libraries, where TMAO was added at 0 mM, 2 mM, 6 mM, and 8 mM end concentrations to the KAPA2G Robust HotStart ReadyMix.
[0022] FIG. 4, FIG. 5, FIG. 6, FIG. 7, FIG. 8, and FIG. 9 show the results from the experiments described in Example 3, as further described below.
[0023] In particular, FIG. 4 shows the total PCR error percentage as determined by WGS analysis of amplified sequencing libraries. TMAO was added to final concentrations of 0 mM, 2 mM, 6 mM, 8 mM and 10 mM, and L-Camitine was added to final concentrations of 50 mM, 100 mM, 200 mM, 300 mM and 400 mM end, to the KAPA EvoAmp ReadyMix.
[0024] FIG. 5 shows the total PCR error percentage as determined by WGS analysis of amplified sequencing libraries. The combinations of TMAO and L-Camitine were as follows: (i) 100 mM L-Camitine + 6 mM TMAO, (ii) 200 mM L-Camitine + 6 mM TMAO, (iii) 300 mM L-Camitine + 6 mM TMAO, (iv) 400 mM L-Camitine + 6 mM TMAO, (v) 2 mM TMAO + 300 mM L-Camitine, (vi) 4 mM TMAO +300 mM L-Camitine, (vii) 6 mM TMAO + 300 mM L-Camitine, (ix) 8 mM TMAO +300 mM L-Camitine, and (x) 10 mM TMAO+300 mM L-Camitine end concentration to the KAPA EvoAmp ReadyMix.
[0025] FIG. 6 shows the coverage uniformity as determined by WGS analysis of amplified sequencing libraries. TMAO added at 0 mM, 2 mM, 4 mM, 6 mM, 8 mM and 10 mM end concentration to the KAPA EvoAmp ReadyMix.
[0026] FIG. 7 shows the coverage uniformity as determined by WGS analysis of amplified sequencing libraries. L-Camitine was added at 0 mM, 100 mM, 200 mM, 300 mM and 400 mM end concentration to the KAPA EvoAmp ReadyMix.
[0027] FIG. 8 shows the coverage uniformity as determined by WGS analysis of amplified sequencing libraries. These studies show the effects of the following combinations of TMAO and L-Camitine added, as follows: (i) 2 mM TMAO + 300 mM L-Camitine, (ii) 4 mM TMAO + 300 mM L-Camitine, (iii) 6 mM TMAO + 300 mM L-Camitine, (iv) 8 mM TMAO + 300 mM L-Camitine, and (iv) 10 mM TMAO + 300 mM L-Camitine end concentration to the KAPA EvoAmp ReadyMix.
[0028] FIG. 9 shows the coverage uniformity as determined by WGS analysis of amplified sequencing libraries. These results show the effects of the following combinations of TMAO and L-Camitine, as follows: (i) 100 mM L-Camitine + 6 mM TMAO, (ii) 200 mM L-Camitine + 6 mM TMAO, (iii) 300 mM L-Camitine + 6 mM TMAO, and (iv) 400 mM L-Camitine + 6 mM TMAO end concentration to the KAPA EvoAmp ReadyMix.DETAILED DESCRIPTION OF THE INVENTION
[0029] Certain embodiments of the present disclosure relate to master mix and / or ready mix solution compositions, for use in nucleic acid amplification reactions, such as PCR. In some embodiments, the master mix or ready mix compositions comprise certain components, such as buffers, salts, chemical compounds that improve nucleic acid hybridization (such as quaternary ammonium salts (e.g, tetramethylammonium chloride (TMAC) and tetramethylammonium oxalate (TMAO)), quaternary ammonium, alcohols, polymerase co-factors, dNTPs, and polymerases. Certain embodiments also include methods of using the master mixes and / or ready mixes in nucleic acid amplification reactions, such as PCR amplifications.
[0030] One embodiment of the disclosure is directed to a master mix composition for amplification of nucleic acids, wherein the composition comprises the following: (a) between about 10-300 mM of a buffer; (b) between about 10-200 mM of a quaternary ammonium compound; (c) between about 2-20 mM of an oxalate salt; and (d) between about 1-5 mM of one or more polymerase co-factors. In another embodiment, the oxalate salt is tetramethylammonium oxalate (TMAO). In another embodiment, the TMAO is at a concentration of between about 2-10 mM. In another embodiment, the composition further comprises the following: (e) between about 50-600 mM of a Carnitine. In another embodiment, the Carnitine may be either the D-Camitine or L-Camitine. In another embodiment, the Carnitine is D-Camitine. In another embodiment, the Carnitine is L-Camitine. In another embodiment, the L-Camitine is at a concentration of between about 50-400 mM. In another embodiment, the quaternary ammonium compound is tetramethylammonium chloride (TMAC). In another embodiment, the composition further comprises the following: (e) one or more DNA polymerases. In another embodiment, the composition further comprises the following: (e) deoxynucleoside triphosphates (dNTPs). In another embodiment, the one or more polymerase co-factors is magnesium ions (Mg2+). In another embodiment, the buffer is a Tris buffer. In another embodiment, the oxalate salt is TMAO, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine. In another embodiment, the quaternary ammonium compound is TMAC. In another embodiment, the oxalate salt is TMAO, the quaternary ammonium compound is TMAC, and the composition further comprises between about 50-600 mM of L-Camitine. In another embodiment, the composition is a polymerase chain reaction (PCR) master mix composition, and the amplification is by polymerase chain reaction (PCR). In anotherembodiment, the disclosure is directed to a method of conducting polymerase chain reaction (PCR), wherein the PCR reaction is conducted in the master mix composition of claim.
[0031] One embodiment of the disclosure is directed a polymerase chain reaction (PCR) master mix composition, wherein the PCR master mix composition comprises the following: (a) between about 10-300 mM of a buffer; (b) between about 10-200 mM of a quaternary ammonium compound; (c) between about 2-20 mM of an oxalate salt; and (d) between about 1-5 mM of one or more polymerase co-factors. In one embodiment, the oxalate salt is tetramethylammonium oxalate (TMAO). In one embodiment, the TMAO is at a concentration of between about 2-10 mM. In one embodiment, the PCR master mix composition further comprises the following: (e) between about 50-600 mM of a Carnitine. In one embodiment, the Carnitine may be either the D-Camitine or L-Camitine. In one embodiment, the Carnitine is D-Camitine. In one embodiment, the Carnitine is L-Camitine. In one embodiment, the L-Camitine is at a concentration of between about 50-400 mM. In one embodiment, the quaternary ammonium compound is tetramethylammonium chloride (TMAC). In one embodiment, the PCR master mix composition further comprises the following: (e) one or more DNA polymerases. In one embodiment, the PCR master mix composition further comprises the following: (e) deoxynucleoside triphosphates (dNTPs). In one embodiment, the one or more polymerase co-factors is magnesium ions (Mg2+). In one embodiment, the buffer is a Tris buffer. In one embodiment, the oxalate salt is TMAO, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine. In one embodiment, the quaternary ammonium compound is TMAC. In one embodiment, the oxalate salt is TMAO, the quaternary ammonium compound is TMAC, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine. In one embodiment, the disclosure is directed to a method of conducting PCR, wherein the PCR reaction is conducted in the PCR master mix composition.
[0032] One embodiment of the disclosure is directed to a PCR master mix composition, wherein the PCR master mix composition comprises the following: (a) between about 10-300 mM of a buffer; (b) between about 10-200 mM of a quaternary ammonium compound; (c) between about 2-20 mM of an oxalate salt; (d) between about 1-5 mM of one or more polymerase co-factors; and (e) between about 50-600 mM of a Carnitine. In one embodiment, the oxalate salt is tetramethyl ammonium oxalate (TMAO). In one embodiment, the TMAO is at a concentration of between about 2-10 mM. In one embodiment, the Carnitine may be either the D-Camitine or L-Camitine. In one embodiment, the Carnitine is D-Camitine. In one embodiment, the Carnitine is L-Camitine. In one embodiment, the L-Carnitine is at a concentration of between about 50-400 mM. In one embodiment, the quaternary ammonium compound is tetramethylammonium chloride (TMAC). In one embodiment, the PCR master mix composition further comprises the following: (f) one or more DNA polymerases. In one embodiment, the PCR master mix composition further comprises the following: (f) deoxynucleoside triphosphates (dNTPs). In one embodiment, the buffer is a Tris buffer. In one embodiment, the one or more polymerase co-factors is magnesium ions (Mg2+). In one embodiment, the oxalate salt is TMAO, and the Carnitine is L-Camitine. In one embodiment, the quaternary ammonium compound is TMAC. In one embodiment, the oxalate salt is TMAO, the quaternary ammonium compound is TMAC, and Carnitine is L-Camitine. In one embodiment, the disclosure is directed to a method of conducting PCR, wherein the PCR reaction is conducted in the PCR master mix composition.
[0033] In another embodiment, the disclosure is directed to a method of amplifying one or more target nucleic acids by PCR, wherein the amplification is conducted in a PCR master mix composition, wherein the PCR master mix composition comprises the following: (a) between about 10-300 mM of a buffer; (b) between about 10-200 mM of a quaternary ammonium compound; (c) between about 2-20 mM of an oxalate salt; and (d) between about 1-5 mM of one or more polymerase co-factors. In one embodiment, the oxalate salt is tetramethylammonium oxalate (TMAO). In one embodiment, the TMAO is at a concentration of between about 2-10 mM. In one embodiment, the PCR master mix composition further comprises the following: (e) between about 50-600 mM of a Carnitine. In one embodiment, the Carnitine may be either the D-Camitine or L-Camitine. In one embodiment, the Carnitine is D-Camitine. In one embodiment, the Carnitine is L-Camitine. In one embodiment, the L-Camitine is at a concentration of between about 50-400 mM. In one embodiment, the quaternary ammonium compound is tetramethylammonium chloride (TMAC). In one embodiment, the method further comprises the following: (e) one or more DNA polymerases. In one embodiment, the method of claim further comprises the following: (e) deoxynucleoside triphosphates (dNTPs). In one embodiment, the one or more polymerase co-factors is magnesium ions (Mg2+). In one embodiment, the buffer is a Tris buffer. In one embodiment, the oxalate salt is TMAO, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine. In one embodiment, the quaternary ammonium compound is TMAC. In one embodiment, the oxalate salt is TMAO, the quaternary ammonium compound is TMAC, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine. In one embodiment, the PCR exhibits improved fidelity and / or improved uniformity across content of variable GC content, ascompared to PCR conducted without the master mix composition. In one embodiment, primer extension during the PCR is performed at 68°C.
[0034] DEFINITIONS
[0035] As used herein, the singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. The term "includes" is defined inclusively, such that "includes A or B" means including A, B, or A and B.
[0036] As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as being inclusive, e.g., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (e.g. "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of or "exactly one of." " Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.
[0037] The terms "comprising," "including," "having," and the like are used interchangeably and have the same meaning. Similarly, "comprises," "includes," "has," and the like are used interchangeably and have the same meaning. Specifically, each of the terms is defined consistent with the common United States patent law definition of "comprising" and is therefore interpreted to be an open term meaning "at least the following," and is also interpreted not to exclude additional features, limitations, aspects, etc. Thus, for example, "a device having components a, b, and c" means that the device includes at least components a, b, and c. Similarly, the phrase: "a method involving steps a, b, and c" means that the method includes at least steps a, b, and c. Moreover, while the steps and processes may be outlined herein in a particular order, the skilled artisan will recognize that the ordering steps and processes may vary.
[0038] As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. Thisdefinition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently "at least one of A and / or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
[0038] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0039] As used herein, the terms "amplification" or "amplify" refer to a process in which a copy number increases. Amplification may be a process in which replication occurs repeatedly over time to form multiple copies of a template. Amplification can produce an exponential or linear increase in the number of copies as amplification proceeds. Exemplary amplification strategies include polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), rolling circle replication (RCA), cascade-RCA, nucleic acid based amplification (NASBA), and the like. Also, amplification can utilize a linear or circular template. Amplification can be performed under any suitable temperature conditions, such as with thermal cycling or isothermally. Furthermore, amplification can be performed in an amplification mixture (or reagent mixture), which is any formulation capable of amplifying a nucleic acid target, if any, in the mixture. PCR amplification relies on repeated cycles of heating and cooling (i.e., thermal cycling) to achieve successive rounds of replication. PCR can be performed by thermal cycling between two or more temperature setpoints, such as a higher denaturation temperature and a lower annealing / extension temperature, or among three or more temperature setpoints, such as a higher denaturation temperature, a lower annealing temperature, and an intermediate extension temperature, among others. PCR can be performed with a thermostable polymerase, such as Taq DNA polymerase. PCR generally produces an exponential increase in the amount of a product amplicon over successive cycles.
[0040] As used herein, the term "complementary" generally refers to the capability for precise pairing between two nucleotides. The term "complementary" refers to the ability to form favorable thermodynamic stability and specific pairing between the bases of two nucleotides at an appropriate temperature and ionic buffer conditions. Complementarity is achieved by distinct interactions between the nucleobases adenine, thymine (uracil in RNA), guanine and cytosine, where adenine pairs with thymine or uracil, and guanine pairs with cytosine. For example, if a nucleotide at a given position of a nucleic acid is capable of hydrogen bonding with a nucleotide of another nucleic acid, then the two nucleic acids are considered to be complementary to one another at that position. Complementarity between two single-stranded nucleic acid molecules may be "partial," in which only some of the nucleotides bind, or it may be complete when total complementarity exists between the single-stranded molecules. A first nucleotide sequence can be said to be the "complement" of a second sequence if the first nucleotide sequence is complementary to the second nucleotide sequence. A first nucleotide sequence can be said to be the "reverse complement" of a second sequence, if the first nucleotide sequence is complementary to a sequence that is the reverse (i.e. , the order of the nucleotides is reversed) of the second sequence.
[0041] As used herein, the terms "nucleic acid" or "polynucleotide" (used interchangeably herein) refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. Unless specifically limited, the terms encompass nucleic acids or polynucleotides including known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Nonlimiting examples of polynucleotides include coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, synthetic polynucleotides, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified, such as by conjugation with a labeling component. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g.,degenerate codon substitutions), alleles, orthologues, SNPs, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0042] As used herein, the term "oligonucleotide," refers to an oligomer of nucleotide or nucleoside monomer units wherein the oligomer optionally includes non-nucleotide monomer units, and / or other chemical groups attached at internal and / or external positions of the oligomer. The oligomer can be natural or synthetic and can include naturally-occurring oligonucleotides, or oligomers that include nucleosides with non-naturally-occurring (or modified) bases, sugar moieties, phosphodiester-analog linkages, and / or alternative monomer unit chiralities and isomeric structures (e.g., 5'- to 2'-linkage, L-nucleosides, a-anomer nucleosides, b- anomer nucleosides, locked nucleic acids (LNA), peptide nucleic acids (PNA)).
[0043] As used herein, the term "substantially" means the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. In some embodiments, "substantially" means within about 2.5%. In some embodiments, "substantially" means within about 5%. In some embodiments, "substantially" means within about 7.5%. In some embodiments, "substantially" means within about 10%. In some embodiments, "substantially" means within about 12.5%. In some embodiments, "substantially" means within about 15%. In some embodiments, "substantially" means within about 20%.
[0043] As used herein, the term "polymerase chain reaction" or "PCR" refers to a biochemical technology or method for amplifying a single or a few copies of a piece of nucleic acids (e.g., DNA) across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. This term is intended to encompass all variations, modifications, and evolutions of the technique known in the art, including, but not limited to, quantitative real-time PCR (qPCR), reverse transcription PCR (RT-PCR), digital PCR (dPCR), droplet digital PCR (ddPCR), nested PCR, multiplex PCR, hot-start PCR, touchdown PCR, assembly PCR, and asymmetric PCR. The process typically involves thermal cycling, consisting of cycles of repeated heating and cooling of the reaction for DNA melting and enzymatic replication of the DNA, and utilizes a reaction mixture comprising a template nucleic acid, primers, a thermostable DNA polymerase, and deoxynucleoside triphosphates (dNTPs). By way of illustration and not limitation, examples of specificcomponents and formats utilized in the polymerase chain reaction include Taq polymerase, Pfu polymerase, SYBR Green dye, TaqMan probes, and various buffering systems such as those containing magnesium chloride or potassium chloride. The term further includes functional equivalents that achieve nucleic acid amplification through enzymatic means, whether performed in a single chamber, a multi-well plate, a microfluidic device, or an emulsion droplet.
[0044] As used herein, the term "master mix" or “ready mix” (used interchangeably) refers to a concentrated or ready -to-use premixed solution containing a combination of reagents and components necessary for performing a biochemical reaction, such as a polymerase chain reaction (PCR) or another nucleic acid amplification technique. The term encompasses any formulation that simplifies the preparation of individual reactions by providing multiple constituents in a single reagent, thereby reducing pipetting or assembly errors and increasing consistency across multiple experimental samples. Components within a master mix typically include, but are not limited to, a thermostable DNA polymerase, deoxynucleoside triphosphates (dNTPs), divalent cations, buffering agents, and optionally, stabilizers, enhancers, or detection dyes. By way of illustration and not limitation, examples of constituents that may be present in a master mix include Taq polymerase, dATP, dCTP, dGTP, dTTP, dUTP, magnesium chloride (MgCh), potassium chloride (KC1), Tris-HCl, bovine serum albumin (BSA), glycerol, betaine, and fluorescent intercalating dyes such as SYBR Green or EvaGreen. The term further includes functional equivalents such as lyophilized or "beaded" master mixes, concentrated stocks (e.g., 2X, 5X, or 10X formulations), and specialized mixes for specific applications like hot-start PCR, high-fidelity PCR, or one-step reverse transcription PCR (RT-PCR).
[0045] As used herein, the term "oxalate salt" refers to a chemical compound formed by the ionic bonding of an oxalate anion (C2O42') or a hydrogen oxalate anion (H C2O42) with one or more cations. The term is intended to encompass all stoichiometric ratios, including mono-oxalate and di-oxalate forms, as well as various physical forms such as anhydrous salts, hydrates, solvates, and crystalline or amorphous polymorphs. This definition includes, but is not limited to, inorganic salts, organic salts, and complex salts where the oxalate moiety acts as a ligand or counterion in a larger molecular or ionic assembly. By way of illustration and not limitation, examples of oxalate salts include tetramethylammonium oxalate (TMAO), sodium oxalate, potassium oxalate, ammonium oxalate, calcium oxalate, magnesium oxalate, and pharmaceutically acceptable oxalate salts of organic bases, such as escitalopram oxalate or naltrexone oxalate. The term further extends to functional derivativesand chemical equivalents that maintain the core oxalate structure while being substituted or coordinated with additional functional groups or metal centers, provided they retain the essential chemical characteristics of an oxalate-based ionic species.
[0046] As used herein, the term "quaternary ammonium compound" refers to a salt of a quaternary ammonium cation consisting of a central positively charged nitrogen atom covalently bonded to four organic groups, which may be alkyl, aryl, or heterocyclic groups, and associated with an appropriate counterion. The term is intended to encompass molecules where the nitrogen atom is part of a saturated or unsaturated ring system, as well as those where the four substituent groups are the same or different, substituted or unsubstituted, and linear, branched, or cyclic in nature. This definition includes all possible salt forms, such as halides, sulfates, carbonates, hydroxides, and organic acid salts, as well as various hydrates, solvates, and crystalline polymorphs thereof. By way of illustration and not limitation, examples of quaternary ammonium compounds include benzalkonium chloride, cetyltrimethylammonium bromide (CTAB), tetramethyl ammonium chloride (TMAC), benzethonium chloride, choline, and polymeric quaternary ammonium compounds such as poly quatemi urn- 1 or polyquatemium-10. The term further extends to functional derivatives, substituted analogs, and structurally related species that maintain a permanent positive charge on a central nitrogen atom, including those utilized as surfactants, phase transfer catalysts, antimicrobial agents, or stabilizers in pharmaceutical or diagnostic formulations.
[0047] As used herein, the term "GC bias" refers to the non-random, disproportionate representation of nucleic acid sequences within a population based on the relative proportion of guanine (G) and cytosine (C) nucleotides contained therein. The term is intended to encompass variations in amplification efficiency, sequencing depth, or library representation that correlate with the GC-content of a target template, including under-representation of GC-rich regions (e.g., >60% GC) and GC-poor / AT-rich regions (e.g., <40% GC). In the context of a diagnostic assay or sequencing method, GC bias describes a deviation from a uniform or theoretical distribution of reads across a genome or transcriptome. By way of illustration and not limitation, GC bias may be influenced or modulated by factors such as thermal cycling parameters, DNA polymerase kinetics, buffer composition (e.g., the presence of betaine, DMSO, or glycerol), fragmentation methods (e.g., enzymatic vs. mechanical), and the specific chemistry of a sequencing platform (e.g., bridge amplification or ion-sensing). The term further includes functional equivalents such as "amplification bias," "sequencedependent coverage variation," or "compositional bias" where the primary driver of the variation is the nucleotide composition of the template.
[0048] As used herein, the term "fidelity" as it relates to amplification of nucleic acids (such as PCR), refers to the accuracy or precision with which a DNA polymerase or a nucleic acid amplification system replicates a template sequence, specifically relating to the ability of the system to incorporate the correct complementary nucleotide at a given position while minimizing the frequency of misincorporations, insertions, or deletions. The term is intended to encompass multiple biochemical mechanisms that contribute to the maintenance of sequence identity, including, but not limited to, the thermodynamic or kinetic discrimination between correct and incorrect nucleoside triphosphates at the polymerase active site and the enzymatic excision of mismatched nucleotides via 3’ — > 5’ exonuclease activity. Fidelity may be characterized or quantified by various metrics, such as error rate (e.g., the number of errors per base pair incorporated), the ratio of polymerization to exonuclease activity, or the percentage of error-free clones generated from a population of amplicons. By way of illustration and not limitation, examples of enzymes or systems exhibiting high fidelity include Pfu polymerase, Phusion DNA polymerase, Q5 High-Fidelity DNA polymerase, KOD polymerase, and engineered variants possessing enhanced proofreading domains. The term further includes functional equivalents and related descriptors such as "replication accuracy," "proofreading efficiency," "base selection specificity," and "sequence integrity maintenance," whether achieved through naturally occurring enzymes, recombinant fusion proteins, or chemical additives that modulate the kinetics of the elongation complex.
[0049] EXAMPLES
[0050] Example 1: Composition of a PCR Master Mix and / or Ready Mix
[0051] A PCR master mix or ready mix was generated with a mixture of components, as shown in Table 1, in FIG. 1. This master mix or ready mix is to be used in the PCR amplification, for example for generation of sequencing library molecules. This master mix or ready mix is formulated at a concentration that is double (i.e., 2x) of which is required for the PCR reaction. This is so that the correct addition of water, sequencing library molecules and DNA oligonucleotides (i.e., primers) will dilute the master mix or ready mix components from a 2x concentration to the intended working concentration (i.e., lx).
[0052] In particular, the master mix or ready mix compositions comprises: (a) a buffer, such as a Tris buffer, at a final concentration of 100 mM; (b) tetramethyl ammonium chloride (or “TMAC”), which is a precipitating element or salt, at a final concentration of 80 mM; (c) tetramethylammonium oxalate (TMAO), at a final concentration of 6 mM; (d) a polymerase co-factor, such as magnesium chloride (i.e., MgCh), at a final concentration of 2.75 mM; (e) a hydrogel, such as gelatin, at a final concentration of 0.04% (v / v); (f) a polyolor alcohol, such as glycerol, at a final concentration of 5% (v / v); (g) quaternary ammonium compound, such as L-Camitine, at a final concentration of 300 mM; (h) dNTPs at a final concentration of 0.2 mM; and (i) a polymerase, (“HiFi polymerase”, at a final concentration of 600 ng (per 50 pl PCR reaction), which is the modified DNA polymerase as described in the following U.S. patents: U.S. Patent Nos. 9,023,633; 9,388,396; and 8,481,685, all of which are incorporated herein, in their entireties.
[0053] The components tetramethylammonium chloride (“TMAC”) and tetramethylammonium oxalate (“TMAO”) have been shown to enhance PCR reactions, as described in Kovarova and Draber, “New specificity and yield enhancer of polymerase chain reactions,” Nucleic Acids Research 28(13):e70 (2000). In particular, TMAC and TMAO are known to improve nucleic acid hybridization.
[0054] The component, carnitine, is a term that generally refers to both L-camitine and its related compounds, which plays a critical role in cellular energy production. L-camitine has a chemical formula of C7H15NO3. Carnitine has been shown to enhance or improve amplification, as described in European Patent No. EP2373804 and U.S. Patent Publication No. US 2012 / 028259, both of which are incorporated herein by reference in their entireties.
[0055] Other enhancers of PCR reactions are disclosed and discussed in U.S. Patent Nos. 6,787,305 and 11,939,623.
[0056] The disclosed master mix or ready mix composition, as shown in FIG. 1, comprises many of the same components that are commonly found in most conventional PCR master mixes or ready mixes, which are commercially available. For example, the disclosed master mix or ready mix, not unlike most PCR master mixes or ready mixes, comprises deoxynucleoside triphosphates (i.e., dNTPs), a buffer or buffer system (e.g., Tris, Tris-HCl, or Tris-SO4), stabilizers / enhancers (e.g., glycerol, gelatin), and polymerase enzymes (e.g., KAPA HiFi polymerase). Notably, however, the disclosed master mix or ready mix also includes an oxalate salt (such as tetramethylammonium oxalate (TMAO)) and a Carnitine (such as L-Camitine). The disclosed master mix or ready mix also includes a quaternary ammonium compound (such as tetramethylammonium chloride (TMAC)).
[0057] The PCR master mix or ready mix, described herein, and containing the components at the concentrations, as recited in Table 1, as depicted in FIG. 1, was tested under the PCR thermal cycling conditions as recited in Table 2, as depicted in FIG. 2. For each PCR cycle, steps 3-5 were taken.
[0058] The PCR master mix and ready mix, described herein, under the thermal cycling conditions recited in Table 2, depicted in FIG. 2, was tested, and showed excellent amplification efficiency for the HiFi polymerase as described in the following U.S. patents: U.S. Patent Nos. 9,023,633; 9,388,396; and 8,481,685, all of which are incorporated herein, in their entireties. Thus, the PCR master mix or ready mix, described herein, is optimized and ideal for the activity of the HiFi polymerase as described in the following U.S. patents: U.S. Patent Nos. 9,023,633; 9,388,396; and 8,481,685, all of which are incorporated herein, in their entireties.
[0059] The PCR master mix or ready mix of FIG. 1 exhibited improvements over the current on-market PCR master mixes or ready mixes, with such improvements including increased PCR fidelity and PCR coverage uniformity, across a range of different GC-content templates, as well as compatibility with both truncated and full-length adapter types (data not shown).
[0060] Example 2: A DNA polymerase family A-based (making use of a DNA polymerase possessing 5’ to 3’ polymerase activity, 5’ to 3’ exonuclease activity, and lacking 3’ to 5’ proofreading ability) PCR ready mix (RM) exhibits improved fidelity and uniformity upon addition of a PCR enhancer, as shown by whole-genome sequencing (WGS) analysis of the amplified DNA libraries
[0061] High quality genomic DNA from Bordetella pertussis (ATCC BAA-589D-5) was sheared via sonication to a mean fragment size of 350 base pairs (bp). Shearing was performed using a Covaris S220 focused-ultrasonicator in a Covaris 96 microTUBE plate (Duty Factor: 10%, Peak Incident Power: 140W, Cycles per Burst: 200) for 90 seconds. Using 100 ng of sheared DNA, libraries were prepared following the KAPA Ev oPrep sample preparation workflow (see instructions for use: KAPA DNA Library Prep Evolved Workflows with fragmented double-stranded DNA; for use with KAPA EvoPrep and KAPA EvoPrep Boost Kits). KAPA Universal Adapters (Material Number: 09063781001) were used for adapter ligation. Adapter-ligated material was diluted 100-fold and assigned a unique sample identification with PCR using KAPA UDI Primer Mixes (Material Number: 09134336001).
[0062] This amplification was conducted using a modified KAPA2G Robust HotStart ReadyMix (Roche Catalog No. 08041113001). The KAPA2G Robust HotStart ReadyMix (Roche Catalog No. 08041113001) comprises a buffer and polymerase co-factors. The modified readymix disclosed herein comprises the KAPA2G Robust HotStart ReadyMix (Roche Catalog No. 08041113001) supplemented with TMAO at final concentrations of 0, 2,6, or 8 mM, in order to assess the impact of TMAO on PCR performance. This modified PCR master mix or ready mix composition comprises many of the same components that are commonly found in most conventional PCR master mixes or ready mixes, which are commercially available. For example, the disclosed base master mix or ready mix, KAPA2G Robust HotStart Ready Mix (Roche Catalog No. 08041113001), not unlike most PCR master mixes or ready mixes, comprises deoxynucleoside triphosphates (i.e., dNTPs), a buffer or buffer system (e.g., Tris, Tris-HCl, or Tris-SO4), stabilizers / enhancers (e.g., glycerol, gelatin), and polymerase enzymes (e.g., KAPA2G Robust DNA Polymerase). Notably, however, the disclosed master mix or ready mix also includes an oxalate salt (such as tetramethylammonium oxalate (TMAO)) and a Carnitine (such as L-Camitine).
[0063] The PCR cycling profile consisted of: (i) initial 95°C for 60 seconds; (ii) followed by 12 cycles of the following cycle: 95°C for 15 seconds; 60°C for 15 seconds; and 72°C for 15 seconds; and (iii) followed by a final extension at 72°C for 1 minute. Amplified sequencing libraries were purified with KAPA HyperPure beads (Material No. 0896385001) and quantified via real-time qPCR using the KAPA Library Quantification Kit (Roche Catalog No. 07960140001) on a Roche LightCycler System (Roche). Alternative sequencing library quantification fluorometric methods were performed using either a Nanodrop 2000 (Thermo Fisher Scientific, Catalog No. ND-2000) or Qubit 2.0 (Thermo Fisher Scientific) with the double stranded DNA (dsDNA) assay (Thermo Fisher Scientific, Catalog No.Q32854). Molecule size distribution of the sequencing library was determined using an Agilent High Sensitivity DNA Kit (Material number 5067-4626) and an Agilent 2100 Bioanalyzer electrophoresis system. Alternatively electrophoretic fragment size analysis was performed using a Perkin Elmer LabChip GX II Touch system, a X-mark labchip (Catalog No. BREVCLS 144006) and HT DNA NGS 3K Reagent kit (Catalog No. BREVCLS960013). Pooled sequencing libraries were denatured and diluted according to manufacturers instructions and sequenced on a NextSeq 200 P2 XLEAP-SBS kit (Illumina Catalogue No.20100985) (300 cycles). The data analysis workflow comprised a primary DNA sequencing pipeline alongside a custom error-profiling module to evaluate ready-mix performance with respect to amplification bias and error. The primary pipeline aligned reads and utilized standard utility toolkits, such as Picard and GATK (e.g., version 4.6.1.0), to evaluate amplification metrics and artifacts. Specifically, tools such as Picard's CollectGcBiasMetrics were employed to assess GC bias, while standard coverage uniformity was computed using Mosdepth to evaluate underrepresented genomic regions. To distinguish true amplification errors from sequencing artifacts, a secondary custom Python script was used that processesthe aligned reads by applying stringent quality filters. This custom module isolates bases using strict thresholds for mapping and base quality, exemplarily requiring a minimum base Q-score of 36 to filter out instrument-induced errors. By restricting the analysis to these high-quality bases and confidently mapped reads, the script isolates true polymerase-introduced substitutions from independent error modes, providing a reliable estimate of the PCR amplification module's fundamental error rate.
[0064] FIG. 3A interrogates the sequencing results, and determines the fidelity of the PCR process, characterized or quantified by various metrics, such as error rate (e.g., the number of errors per base pair incorporated, as reflected in total error percentage, along the y-axis of FIG. 3 A. These studies indicate that the introduction of TMAO into the KAPA2G Robust HotStart Ready Mix reduced the total error rate during library amplification, as depicted in FIG. 3 A. This reduction in PCR error (i.e., the improved fidelity) followed a dose-dependent trend, with sequential increases in TMAO concentration (2 mM, 6 mM, and 8 mM) yielding stepwise improvements in fidelity. Thus, the introduction of TMAO in PCR master mixes or ready mixes results in reduced errors (i.e., improved fidelity) in PCR, in a dose-dependent manner. FIG. 3B interrogates the sequencing results to examine GC bias, by examining the normalized coverage as a product of GC content, showing normalized coverage along the y-axis and GC content along the x-axis. By way of background, GC bias refers to the disproportionate representation of genomic regions based on their guanine-cytosine (G-C) content. In the context of library amplification followed by sequencing, it would be ideal if every fragment of a genome would be amplified and sequenced with equal efficiency. That is, ideally, a PCR assay should exhibit low GC bias, and instead, should exhibit better uniform coverage. However, the physical properties of G-C base pairs (which share three hydrogen bonds compared to the two in A-T pairs) create significant deviations from this ideal. As can be seen in FIG. 3B, the analysis of GC content distribution revealed that TMAO promotes more uniform amplification of high-GC molecules. Specifically, increasing the final TMAO concentration led to a corresponding improvement in normalized coverage for high-GC content, even approaching the theoretical optimum of 1.
[0065] Taken together, FIG. 3A and FIG. 3B demonstrate that the introduction and presence of TMAO in master mixes or ready mixes results in improved fidelity and improved uniformity in coverage (i.e., reduced GC bias). Thus, this example unequivocally demonstrates that the addition of TMAO to the KAPA2G Robust HotStart Ready Mix yields dose-dependent improvements in both fidelity and coverage uniformity. This correlation highlights the multifaceted role of TMAO in enhancing PCR performance, offering criticaladvantages for next generation sequencing (NGS) applications that require high accuracy and the unbiased representation of challenging genomic templates.
[0066] Example 3: DNA polymerase family B-based (making use of a DNA polymerase possessing 5’ to 3’ polymerase activity with 3’ to 5’ proofreading ability) PCR ready mix (RM) with improved fidelity and uniformity performance due to addition of a PCR enhancer, as determined by whole genome sequencing (WGS) analysis of PCR-amplified sequencing DNA library molecules
[0067] High-quality genomic DNA from Bordetella pertussis (ATCC BAA-589D-5) was sheared via sonication to a mean fragment size of 350 base pairs (bp). Shearing was performed using a Covaris S220 focused-ultrasonicator in a Covaris 96 microTUBE plate (Duty Factor: 10%, Peak Incident Power: 140W, Cycles per Burst: 200) for 90 seconds. Using 100 ng of sheared DNA, libraries were prepared following the KAPA Ev oPrep sample preparation workflow (see instructions for use: KAPA DNA Library Prep Evolved Workflows with fragmented double-stranded DNA; for use with KAPA EvoPrep and KAPA EvoPrep Boost Kits). KAPA Universal Adapters (Material No. 09063781001) were used for adapter ligation. Adapter-ligated material was diluted 100-fold, and assigned a unique sample identification with PCR using KAPA UDI Primer Mixes (Material No.09134336001).
[0068] This amplification was conducted using a modified KAPA EvoAmp ReadyMix (Roche catalogue number: 10613572001). The KAPA EvoAmp ReadyMix (Roche catalogue number: 10613572001) comprises a buffer and polymerase co-factors. The modified readymix disclosed herein comprises the KAPA EvoAmp ReadyMix (Roche catalogue number: 10613572001) supplemented with: (i) TMAO at a final concentration of 0, 2, 6, 8, or 10 mM; and (ii) L-Camitine at a final concentration of 50, 100, 200, 300, or 400 mM, in order to assess the impact of TMAO, or L-Camitine, or the combination of TMAO and L-Camitine on PCR performance. This modified PCR master mix or ready mix composition comprises many of the same components that are commonly found in most conventional PCR master mixes or ready mixes, which are commercially available. For example, the disclosed base master mix or ready mix, KAPA EvoAmp ReadyMix (Roche catalogue number: 10613572001, not unlike most PCR master mixes or ready mixes, comprises deoxynucleoside triphosphates (z.e., dNTPs), a buffer or buffer system (e.g., Tris, Tris-HCl, or Tris-SCL). stabilizers / enhancers (e.g., glycerol, gelatin), and polymerase enzymes (e.g., KAPA HiFi polymerase). Notably, however, the disclosed master mix or ready mix also includes an oxalate salt (such as tetramethylammonium oxalate (TMAO)) anda Carnitine (such as L-Carnitine). The disclosed master mix or ready mix also includes a quaternary ammonium compound (such as tetramethylammonium chloride (TMAC)).
[0069] The PCR cycling profile consisted of: (i) initially 98°C for 45 seconds; (ii) 12 cycles of the following: 98°C for 15 seconds, 60°C for 30 seconds, and 68°C for 30 seconds; and (iii) followed by a final extension at 72°C for 1 minute. It is noted that the primer extension steps during thermal cycling are performed at 68°C, whereas the temperature for the final extension step is more conventionally conducted at 72°C. Thus, the primer extension temperature for thermal cycling is optimized at 68°C for this particular modified KAPA EvoAmp Ready Mix. It is noted that the final extension step was also conducted at 68°C, and results were not any different than when the final extension step was conducted at 72°C. Amplified sequencing libraries were purified with KAPA HyperPure beads (Material No. 08963835001) and quantified via real-time qPCR using the KAPA Library Quantification Kit (Roche Catalog No. 07960140001) on a Roche LightCycler system (Roche). Alternatively electrophoretic fragment size analysis was performed using a Perkin Elmer LabChip GX II Touch system, aX-mark labchip (Catalog No. BREVCLS 144006) and HT DNA NGS 3K Reagent kit (Catalog No. BREVCLS960013). Sequencing library molecule size distribution was determined using an Agilent High Sensitivity DNA Kit (Material No. 5067-4626) and an Agilent 2100 Bioanalyzer electrophoresis system.Alternatively electrophoretic fragment size analysis was performed using a Perkin Elmer LabChip GX II Touch system, a X-mark labchip (Catalog No. BREVCLS144006) and HT DNA NGS 3K Reagent kit (Catalog No. BREVCLS960013). Pooled sequencing libraries were denatured and diluted according to manufacturers instructions, and loaded on aNextSeq 500 / 550 Mid Output Kit v2.5 (300 Cycles) (Illumina Catalog No. 20024907) kit and sequenced on aNextSeq 550 System platform (Illumina). The data analysis workflow comprised a primary DNA sequencing pipeline alongside a custom error-profiling module to evaluate ready -mix performance with respect to amplification bias and error. The primary pipeline aligned reads and utilized standard utility toolkits, such as Picard and GATK (e.g., version 4.6.1.0), to evaluate amplification metrics and artifacts. Specifically, tools such as Picard's CollectGcBiasMetrics were utilized to assess GC bias, while standard coverage uniformity was computed using Mosdepth to evaluate underrepresented genomic regions. To distinguish true amplification errors from sequencing artifacts, a secondary custom Python script was used that processes the aligned reads by applying stringent quality filters. This custom module isolates bases using strict thresholds for mapping and base quality, exemplarily requiring a minimum base Q-score of 36 to filter out instrument-induced errors.By restricting the analysis to these high-quality bases and confidently mapped reads, the script isolates true polymerase-introduced substitutions from independent error modes, providing a reliable estimate of the PCR amplification module's fundamental error rate.
[0070] The results of these experiments demonstrate that the introduction of TMAO into the EvoAmp Ready Mix significantly increased fidelity performance in sequencing library PCR amplification, as shown in FIG. 4. This improvement followed a clear dosedependent profile; as TMAO concentrations were scaled from 2 mM to 10 mM, a corresponding stepwise reduction in the total PCR error rate was observed. By contrast, L-Camitine as a standalone additive exerted negligible influence on fidelity. Further analysis making use of scaling L-Camitine, in the context of a fixed 6 mM TMAO, and scaling TMAO in context of a fixed 300 mM L-Camitine, shows that error reduction (i.e., improved fidelity) is attributed mainly to the addition of TMAO, as shown in FIG. 5. Furthermore the effect of these additives on coverage uniformity in a high GC genome was also examined. The results of this examination demonstrated that TMAO showed an improvement in coverage uniformity in high GC regions toward the ideal value of 1, as shown in FIG. 6. Furthermore, these results demonstrate that the addition of L-Camitine significantly improved coverage uniformity for high-GC sequences in a dose-dependent manner, as shown in FIG. 7. TMAO and L-Camitine addition also improved uniformity when scaling L-Camitine dosage in context of 6 mM TMAO and scaling TMAO dosage in context of 300 mM L-Camitine, as shown in FIG. 8 and FIG. 9.
[0071] These studies unequivocally demonstrate that TMAO acts as the primary driver for improved PCR amplification fidelity, as seen in FIG. 3A, FIG. 4, and FIG. 5. Additionally, these studies, taken together, also demonstrate that the combinatorial effect of TMAO and L-Camitine results in the most favorable outcome for both PCR fidelity and uniformity, across content of variable GC content.
[0072] The results indicate that the disclosed PCR master mix or ready mix exhibits improvements over the current on-market PCR master mixes or ready mixes, with such improvements including increased PCR fidelity and PCR coverage uniformity, across a range of different GC-content templates, as well as compatibility with both truncated and full-length adapter types. Furthermore, in the context of human sequencing, the improvements also include better performance on coding regions, clinically relevant regions, tandem repeats, and difficult-to-sequence promoters.
[0073] Thus, the current disclosure is directed to a PCR master mix or ready mix, which contains an oxalate salt (such as TMAO) and a Carnitine (such as L-Camitine), andthat represents a significant improvement over the art, when measured by a number of performance metrics, such as fidelity and coverage uniformity.
[0074] While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be clear to one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention. For example, all the techniques and apparatus described above can be used in various combinations. All publications, patents, patent applications, and / or other documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, and / or other document were individually indicated to be incorporated by reference for all purposes.
Claims
PATENT CLAIMS1. A master mix composition for amplification of nucleic acids, wherein the composition comprises the following:(a) between about 10-300 mM of a buffer;(b) between about 10-200 mM of a quaternary ammonium compound;(c) between about 2-20 mM of an oxalate salt; and(d) between about 1-5 mM of one or more polymerase co-factors.
2. The composition of claim 1, wherein the oxalate salt is tetramethyl ammonium oxalate (TMAO).
3. The composition of claim 2, wherein the TMAO is at a concentration of between about 2-10 mM.
4. The composition of claim 1, further comprising the following:(e) between about 50-600 mM of a Carnitine.
5. The composition of claim 4, wherein the Carnitine may be either the D-Camitine or L-Camitine.
6. The composition of claim 5, wherein the Carnitine is D-Camitine.
7. The composition of claim 5, wherein the Carnitine is L-Camitine.
8. The composition of claim 7, wherein the L-Camitine is at a concentration of between about 50-400 mM.
9. The composition of claim 1, wherein the quaternary ammonium compound is tetramethylammonium chloride (TMAC).
10. The composition of claim 1, further comprising the following:(e) one or more DNA polymerases.
11. The composition of claim 1, further comprising the following:(e) deoxynucleoside triphosphates (dNTPs).
12. The composition of claim 1, wherein the one or more polymerase co-factors is magnesium ions (Mg2+).
13. The composition of claim 1, wherein the buffer is a Tris buffer.
14. The composition of claim 1, wherein: the oxalate salt is TMAO, and the PCR master mix composition further comprises between about 50-600 mM of L-Camitine.
15. The composition of claim 14, wherein the quaternary ammonium compound is TMAC.
16. The composition of claim 1, wherein: the oxalate salt is TMAO, the quaternary ammonium compound is TMAC, and the composition further comprises between about 50-600 mM of L-Camitine.
17. The composition of claim 1, wherein the composition is a polymerase chain reaction (PCR) master mix composition, and the amplification is by polymerase chain reaction (PCR).
18. A method of conducting polymerase chain reaction (PCR), wherein the PCR reaction is conducted in the master mix composition of claim 1.
19. A PCR master mix composition, wherein the PCR master mix composition comprises the following:(a) between about 10-300 mM of a buffer;(b) between about 10-200 mM of a quaternary ammonium compound;(c) between about 2-20 mM of an oxalate salt;(d) between about 1-5 mM of one or more polymerase co-factors; and(e) between about 50-600 mM of a Carnitine.
20. The PCR master mix composition of claim 19, wherein the oxalate salt is tetramethylammonium oxalate (TMAO).
21. The PCR master mix composition of claim 20, wherein the TMAO is at a concentration of between about 2-10 mM.
22. The PCR master mix composition of claim 19, wherein the Carnitine may be either the D-Camitine or L-Camitine.
23. The PCR master mix composition of claim 22, wherein the Carnitine is D-Camitine.
24. The PCR master mix composition of claim 22, wherein the Carnitine is L-Camitine.
25. The PCR master mix composition of claim 24, wherein the L-Camitine is at a concentration of between about 50-400 mM.
26. The PCR master mix composition of claim 19, wherein the quaternary ammonium compound is tetramethylammonium chloride (TMAC).
27. A method of amplifying one or more target nucleic acids by PCR, wherein the amplification is conducted in a PCR master mix composition, wherein the PCR master mix composition comprises the following:(a) between about 10-300 mM of a buffer;(b) between about 10-200 mM of a quaternary ammonium compound;(c) between about 2-20 mM of an oxalate salt; and(d) between about 1-5 mM of one or more polymerase co-factors.
28. The method of claim 27, wherein the oxalate salt is tetramethylammonium oxalate (TMAO).
29. The method of claim 28, wherein the TMAO is at a concentration of between about 2-10 mM.
30. The method of claim 27, wherein the PCR master mix composition further comprising the following:(e) between about 50-600 mM of a Carnitine.
31. The method of claim 30, wherein the Carnitine may be either the D-Camitine or L-Camitine.
32. The method of claim 31, wherein the Carnitine is D-Camitine.
33. The method of claim 31, wherein the Carnitine is L-Camitine.
34. The method of claim 33, wherein the L-Camitine is at a concentration of between about 50-400 mM.
35. The method of claim 27, wherein the quaternary ammonium compound is tetramethylammonium chloride (TMAC).
36. The method of claim 27, wherein the PCR exhibits improved fidelity and / or improved uniformity across content of variable GC content, as compared to PCR conducted without the master mix composition.
37. The method of claim 27, wherein primer extension during the PCR is performed at 68°C.
